Hepatitis C Therapy - SciClone Reports Results from First ZADAXIN Phase 3 Hepatitis C Trial

SciClone Reports Results from First ZADAXIN Phase 3 Hepatitis C Trial
Pharma Live - SAN MATEO, Calif. -- December 14, 2005 -- SciClone Pharmaceuticals, Inc. ( with pegylated interferon alpha to treat patients with hepatitis C virus (HCV) who have failed previous interferon-based

Legal blow in fight for hepatitis C inquiry
PA News via The Scotsman Online - A judge refused to break Scottish legal ground by protecting relatives of three victims against expenses of about 10,000 each should their court action against the Executive fail. why hundreds of people contracted hepatitis C through contaminated blood transfusions in

SciClone stock falls on hepatitis drug data
AP via Seattle Post Intelligencer - trial data for the company's drug to treat hepatitis C liver disease showed no significant benefit to its said trial data for its hepatitis C treatment drug Zadaxin didn't show

SciClone says drug misses trial targets, shares plunge
Reuters - said its experimental drug Zadaxin to treat Hepatitis C infection did not show statistically significant results in